最近饮酒与饮酒障碍作为轻度认知障碍中姿势震和不稳定的可修改风险因素:一项初步研究
Edith V Sullivan1, Stephanie A Sassoon1,2, Rosemary Fama1,2
1Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA.
Alcohol, clinical & experimental research
|November 28, 2025
概括
酒精使用障碍 (AUD) 与轻度认知障碍 (MCI) 相结合,显著恶化姿势不稳定和,增加跌倒风险. 患有AUD史的人最近喝酒是这些平衡赤字的可修改风险因素.
科学领域:
- 神经学 神经学
- 老年学是一门学科.
- 公共卫生 公共卫生
背景情况:
- 酒精消费是痴呆症的重要危险因素,并加剧了现有的健康问题.
- 轻度认知障碍 (MCI) 往往是痴呆症的先发症,其与危险饮酒的并发症研究不足.
- 这种并发症可能会导致与年龄相关的运动衰退,发病率和死亡率.
研究的目的:
- 调查酒精使用障碍 (AUD) 对轻度认知障碍 (MCI) 和无轻度认知障碍 (MCI) 患者的姿势稳定性的影响.
- 确定AUD是否会加剧MCI患者与年龄相关的运动衰退和平衡缺陷.
主要方法:
- 一个混合的横截面/纵横分析,涉及381个平衡平台测试会议.
- 参与者包括对照组,MCI,MCI + AUD和AUD组 (45-90岁).
- 在各种条件下评估平衡,包括静态站立和认知任务.
主要成果:
- 对照显示,随着年龄的增长,姿势不稳定性和震增加.
- 在平衡指标中,MCI集团与控制没有区别.
- 在MCI+AUD和AUD组中,与年龄相关的对姿势稳定的影响显著增加,特别是在具有挑战性的条件下.
结论:
- 年龄会影响姿势的稳定性,特别是在具有挑战性的条件下.
- 患有AUD的MCI个体表现出与仅患有AUD的人相比的余额赤字.
- 患有AUD史的个体最近的酒精消费是姿势不稳定的可修改风险因素,增加了跌倒风险和痴呆症的责任.
相关概念视频
CNS Depressants: Alcohol and Nicotine
1000
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1000
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Depressants
367
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
367
Substance Use Disorders Affecting Sleep
369
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
369
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764


